Dysregulation of CD30 + T cells by leukemia impairs isotype switching in normal B cells
Class switching substitutes the immunoglobulin (Ig) heavy chain (H) constant region µ (Cµ) with Cγ or Cα, thereby endowing specific antibodies with new effector functions that are critical for the clearance of invading microorganisms 1 . IgD + IgM + naïve B cells undergo switching to IgG and IgA upon CD40 engagement by CD40 ligand (CD40L, or CD154)
1,2 , a tumor necrosis factor (TNF) ligand which is expressed by CD4 + T cells a few hours after T cell antigen receptor (TCR) engagement by antigen-presenting cells (APCs) 3 . Engagement of CD40 by CD40L recruits TNF receptor-associated factor 2 (TRAF2), TRAF3, TRAF5 and TRAF6 as well as TRAF-associated nuclear factor-κB (NF-κB) activator (TANK) to the CD40 cytoplasmic domain [4] [5] [6] . By activating downstream kinases, including NF-κB-inducing kinase (NIK) and IκB kinase (IKK), CD40-bound TRAFs elicit the degradation of IκB, a cytoplasmic inhibitor of NF-κB, and the subsequent nuclear translocation of NF-κB 7 . By activating the CD40-responsive elements of CH gene promoters, NF-κB initiates the critical events that lead to class-switch DNA recombination (CSR), including germline IH-CH transcription 1, 8 . Chronic lymphocytic leukemia (CLL) is a chronic B cell lymphoproliferative disorder that is associated with hypogammaglobulinemia, impaired class switching to IgG and IgA and increased susceptibility to bacterial infections 9 . It has been suggested that CLL B cells impair antibody production by diluting normal B cells 10 . However, hypogammaglobulinemia is not always associated with massive leukemic infiltration of lymphoid organs, which suggests that additional mechanisms must be involved in the immune defects that are secondary to CLL. Some studies show that, in CLL, T cells display an impaired helper activity 11 that is possibly secondary to leukemia-induced downregulation of CD40L 12 . Others show that in CLL, T or natural killer (NK) cells display enhanced suppressor functions [13] [14] [15] . Despite these findings, the pathogenesis of CLL-associated immunodeficiency remains elusive.
Four days after TCR engagement and exposure to interleukin 4 (IL-4), both CD4 + and CD8 + T cells express CD30 16 , a member of the TNF receptor (TNFR) superfamily 17 . When engaged by CD30L (CD153) 17, 18 , CD30 signaling mediates the negative selection of thymic T cells 19 and inhibits the clonal expansion of peripheral T cells 20 by down-regulating CD28 21 , impairing TRAF2-mediated activation of NF-κB 22 , down-modulating c-Myc 23 and/or inducing TNF-α-TNFR1 (CD120a)-dependent apoptosis 24, 25 . In addition, CD30 signaling modulates cellular immunity by down-regulating the expression of Fas ligand (FasL, or CD95L) and perforin and by altering the trafficking of cytotoxic T and NK cells 23 . Finally, T cell CD30 inhibits IgG and IgA production by engaging CD30L on CD40L-activated B cells 26 , which suggests that CD30-CD30L interaction limits the overall immune response by delivering bidirectional inhibitory signals.
The relevance of CD30 in the pathogenesis of immune deficiencies is suggested by the dysregulated expansion of CD30 + T cells in AIDS and Omenn's syndrome, a congenital form of severe-combined immune deficiency 27 . The recent observation that CD30 is up-regulated in T cells from CLL patients 28 prompted us to hypothesize that CD30-CD30L interaction plays a role in CLL-associated hypogammaglobulinemia. We show here that, compared to T cells from healthy subjects, T cells from CLL patients express CD30 at an earlier time point and at increased density. This is mainly because of the ability of leukemic B cells to up-regulate T cell CD30 through an OX40L • february 2001
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(CD134L) and IL-4-dependent mechanism. These leukemia-induced CD30 + T cells inhibit Sµ→Sγ and Sµ→Sα CSR by inducing CD30L-dependent CD40-inhibitory signals in normal (nonmalignant) IgD + B cells. In addition, CD30L engagement enhances the TNF-α-dependent growth of leukemic B cells, which suggests that, in CLL, the dysregulation of CD30-CD30L interaction contributes to the pathogenesis of both immunodeficiency and accumulation of leukemic B cells.
Results

CD8
+ CD28 + CD30 + T cells are increased in CLL CD8 + CD28 -T cells, an NK-like T cell subset with potent B and T cell suppressor activity, undergo oligoclonal expansion in aged subjects and CLL patients 29, 30 . We found that, compared to age-matched healthy subjects, CLL patients display an increased proportion of peripheral blood CD8 + CD28 -T cells (TS2) together with an inverted CD8 + CD28 + T cell (TS1) to TS2 ratio (Fig. 1a,b) . Normal TS2 cells and CLL TS2 cells expressed more CD30 than normal TS1 cells. In addition, CLL TS2 cells expressed more CD30 than normal TS2 cells. Finally, CLL TS2 cells expressed increased IL-4 receptor α chain (IL-4Rα, or CD124) and IL-4, which is a critical inducer of T cell CD30 16 . Because T cell CD30 negatively modulates the immune response 20, 23, 26 , we verified the ability of CD30 + TS2 cells to inhibit CSR. Normal IgD + B cells induced extrachromosomal Sγ-Sµ reciprocal DNA recombination products (switch circles) 4 days after exposure to recombinant human trimeric CD40L (htCD40L) and IL-4 (Fig. 1c) . Normal TS2 cells or CLL TS2 cells, but not normal TS1 cells or CLL TS1 cells, inhibited htCD40L-induced Sγ-Sµ CSR. This inhibitory effect was not associated with increased B cell apoptosis and could be reversed by preincubating CLL TS2 cells with blocking monoclonal antibodies (mAbs) to CD30 but not to the TS2 cell-associated marker CD56 29, 30 . In addition, it could be reproduced by agonistic mAbs to CD30L but not to OX40L (a CD30L-like TNFL expressed by activated B cells) 31 . When incubated with normal IgD + B cells and cytokines, both normal CD4 + CD40L + T helper (TH) cells and CLL TH cells induced Sµ→Sα and Sµ→Sγ CSR as well as IgG and IgA production (Fig. 2a) . Both normal TS2 cells and CLL TS2 cells inhibited THinduced CSR. In addition, CLL TS2 cells, but not CLL TS1 cells, downregulated CLL TH cell-induced expression of Iγ1-Cγ1 and Iα1-Cα1, but not Igβ (CD79b), transcripts (Fig. 2b) . This inhibitory effect was reversed by preincubating CLL TS2 cells with blocking monoclonal anti-CD30 but not anti-CD56. Consistent with the observation that CLL TS2 cells inhibit CSR more efficiently than normal TS2 cells (Figs. 1c and 2a) , CLL TS2 cells expressed more CD30 than normal TS2 cells upon incubation with normal IgD + B cells, htCD40L and cytokines (Fig. 2c) . Thus, in CLL patients, the increased numbers of TS2 cells suppress CD40L-induced immunoglobulin class-switching in nonmalignant B cells through a CD30-CD30L-dependent mechanism. 
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Normal B cell CD30L inhibits CD40 signaling
Germline Iγ3-Cγ3 transcription is synergistically induced by CD40L and IL-4 through activation of a CD40 responsive element (RE) and a partially overlapping IL-4R RE within the Cγ3 gene promoter 8 . These CD40 and IL-4 REs consist of two tandemly arrayed NF-κB binding sites and a signal transducer and activator of transcription 6 (STAT6) binding site, respectively 8 . We show here that in the presence of CLL TS2 cells, but not CLL TS1 cells, normal IgD + B cells down-regulated the htCD40L and IL-4-induced expression of germline Iγ3-Cγ3 transcripts and NF-κB binding to the Cγ3 CD40 RE (Fig. 3a) . In contrast, both CLL TS2 cells and normal TS2 cells did not affect the binding of STAT6 to the Cγ3 IL-4R RE. The CLL TS2 cell-mediated inhibition of NF-κB activation was dependent upon CD30-CD30L interaction. This was because it could be reversed by preincubating CLL TS2 cells with blocking monoclonal anti-CD30 and reproduced by an agonistic monoclonal anti-CD30L. In htCD40L-induced IgD + CL-01 B cells, the activation of a minimal promoter that contained either the Cγ3 CD40 RE or two tandemly arrayed NF-κB-binding sites from the Igκ gene promoter was inhibited by CD30L cross-linking (Fig. 3b) . In similarly activated CL-01 B cells, CD30L engagement inhibits the htCD40L-induced activation of the full-length Cγ3 gene promoter 26 . Thus, CLL TS2 cells might induce CD30-dependent inhibition of Iγ3-Cγ3 transcription by interfering with the CD40-NF-κB-dependent pathway.
In normal IgD + B cells, cross-linking of CD30L down-regulated the IL-4 and/or htCD40L-induced association of TRAF2, TRAF3, TRAF5, TRAF6 and TANK to CD40, dampened the kinase activity of IKKα and up-regulated the expression of IκBα without affecting that of NIK or IKKα (Fig. 3c) . Thus, in normal IgD + B cells, engagement of CD30L alters the CD40L-induced assembly of the CD40-TRAF signaling complex and inhibits the IKK-mediated activation of NF-κB.
Leukemic B cells up-modulate T cell CD30
Consistent with a recent report 12 , we found that leukemic CLL B cells modulate the expression of critical T cell activation molecules including CD30 and CD40L (Fig. 4) . After incubation with monoclonal anti-CD3, gated CLL CD3 + CD4 + peripheral blood mononuclear cells (PBMCs) expressed more CD30 (Fig. 4a ) and less CD40L (Fig. 4e) than normal CD3 + CD4 + PBMCs. In contrast, CD25 (IL-2Rα) was comparable on both CLL CD3 + CD4 + and normal CD3 + CD4 + PBMCs (Fig. 4i) . After purification (B cell depletion) and exposure to a monoclonal anti-CD3, CLL CD4 + T cells and normal CD4 + T cells expressed comparable amounts of CD30, CD40L and CD25 (Fig.  4b ,f,j, respectively). However, purified CLL CD4 + T cells expressed less CD30 and more CD40L (Fig. 4b,f) than CLL CD3 + CD4 + PBMCs (Fig. 4a,e) . When activated in the presence of increasing numbers of leukemic CLL B cells, both purified CLL CD4 + T cells and normal CD4 + T cells progressively up-regulated CD30 ( Fig. 4c ) and downregulated CD40L (Fig. 4g ) but expressed constant amounts of CD25 (Fig. 4k) . Increasing numbers of fibroblasts or different concentrations of CLL B cell-derived supernatants could not up-regulate CD30 or down-regulate CD40L on both purified CLL CD4 + T cells and normal CD4 + T cells (Fig. 4d ,h,l and not shown). These findings suggest that leukemic CLL B cells up-modulate CD30 and down-regulate CD40L on TH cells in a contact-dependent fashion.
Leukemia-induced CD30 inhibits class switching
To verify whether leukemic B cell-induced CD4 + CD30 + T cells inhibit immunoglobulin class-switching in a CD30-dependent fashion, T1, T2, T3 and T4 cell fractions were sorted from cultures in which CD4 + T cells from CLL patients had been incubated for 120 h with leukemic B cells at a 1:0.25 (T1), 1:0.5 (T2), 1:1 (T3), or 1:4 (T4) T:B cell ratio (Fig. 4c) . These purified T1, T2, T3 and T4 cells were fixed, preincubated with MOPC-21 or blocking monoclonal anti-CD30 and tested for their ability to modulate IgG production in normal B cells. (Fig. 5a) . Consistent with their increased CD30 (Fig. 4c) , T4 cells inhibited IgG production more efficiently than T3 and T2 cells. (Fig. 5c,d ). In addition, in CD3-activated CLL CD4 + T cells, CD30 was up-regulated more effectively by engagement of OX40 or both OX40 and CD28 than by CD28 alone (Fig. 5e) . 
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In antigen-activated T cells, OX40-OX40L interaction up-regulates IL-4 31 , a known CD30 inducer 16 . Accordingly, neutralizing antibodies to IL-4, but not interferon-γ (IFN-γ), virtually abolished CD30 up-regulation on CLL CD4 + T cells activated by monoclonal anti-CD3 in the presence of leukemic B cells (Fig. 5b) . Finally, TAPI (TNF-α protease inhibitor), an inhibitor of TNF-α converting enzyme (TACE)-mediated CD30 cleavage 32 , did not affect the expression of T cell CD30 (Fig.  5b) . Thus, leukemic B cells up-regulate T cell CD30 in an OX40L-and IL-4-dependent fashion.
CD30-dependent down-regulation of CD40L
When activated in the presence of progressively increasing numbers of leukemic CLL B cells, CD4 + T cells up-regulate CD30 and, concomitantly, down-regulate CD40L (Fig. 4c,g ). This prompted us to hypothesize that engagement of CD30 on CD4 + T cells by CD30L on malignant CLL B cells 18, 33 down-regulates CD40L. In the presence of leukemic CLL B cells (1:4 T:B cell ratio) and blocking monoclonal anti-CD30 (Fig. 6a) , CLL CD4 + T cells expressed more CD40L than similarly induced CD4 + T cells incubated with control MOPC-21 mAb (Fig. 6a) . Consistent with this, immobilized agonistic monoclonal anti-CD30, but not MOPC-21, down-regulated CD40L transcripts and surface protein in CD3-activated CD4 + Jurkat D1.1 T cells. The expression of CD30 transcripts and surface protein was not affected by the agonistic monoclonal anti-CD30 (Fig. 6b,c) . After a 12-h preincubation with immobilized anti-CD3 alone, both normal CD4 + T cells and CLL CD4 + T cells induced comparable amounts of CD40L-dependent IgG from normal IgD + B cells (Fig. 6d) . 
CD30L engagement enhances leukemic B cell growth
Leukemic CLL B cells undergo TNFR2-mediated NF-κB activation and proliferation when exposed to TNF-α 34, 35 . In the presence of an agonistic anti-CD30L but not MOPC-21 mAb, leukemic CLL B cells, unlike nonmalignant IgD + B cells, up-regulated the htCD40L and IL-4-induced TNF-α secretion, proliferation, survival and NF-κB nuclear translocation (Fig. 7 and data not shown) . Neutralizing antibodies to TNF-α or TNFR2, but not IL-6 or IL-6Rα, reversed the CD30L-mediated up-regulation of htCD40L and IL-4-induced proliferation, survival and NF-κB nuclear translocation. Thus, CD30L-mediated signals enhance the TNF-α-mediated accumulation of malignant B cells.
Discussion
These studies define a new mechanism for the pathogenesis of CLLassociated immunodeficiency. They suggest that, in CLL, dysregulated CD30-CD30L interaction impairs the CD40-mediated differentiation of residual nonmalignant IgD + B cells into IgG-and IgA-producing cells.
A few days after TCR engagement by antigen, CD4 + T cells express CD30 16 that, by engaging CD30L on B cells, would physiologically limit IgG and IgA production 26 . When activated in the presence of leukemic CLL B cells, CD4 + T cells up-regulate CD30 at earlier time points and express more CD30. This abnormal CD30 expression would result from a complex sequence of events. Our findings suggest that, in CLL patients, antigen-activated CD4 + T cells transiently induce CD40L that rapidly up-regulates OX40L on CD40-expressing malignant B cells (Fig. 8) . Leukemic B cell OX40L will then engage OX40 on CD4 + T cells and elicit IL-4 secretion 31 that, in turn, induces CD30 on both CD4 + and CD8 + T cells. These CD30 + T cells impair isotype switching by delivering CD30L-mediated inhibitory signals in nonmalignant IgD + B cells. In addition, isotype switching will be reduced due to the leukemic B cell CD30L-mediated down-regulation of CD40L on CD4 + CD30 + T cells. Thus, our findings indicate that, in CLL, hypogammaglobulinemia would stem from the leukemia-induced dysregulation of an otherwise physiological suppressor pathway and provide a mechanistic explanation for the acquired CD40L deficiency observed in CLL patients 12 . In CLL patients, CD8 + CD28 -T cells are increased and express more CD30 28 . These NK-like cells up-regulate CD30, down-regulate CD28, become less responsive to mitogenic stimuli and acquire immunosuppressive activity as a consequence of persistent exposure to antigen 28, 30, 36 . It is tempting to speculate that, by increasing the proportion of anergic CD8 + CD28 -suppressor T cells and their CD30-dependent immunoglobulin class-switch-inhibitory activity, chronic stimulation by antigen(s) plays a relevant role in the pathogenesis of CLL-associated immune defects. Consistent with this, earlier reports suggested that, in CLL patients, hypogammaglobulinemia stems from the enhanced ability of chronically activated suppressor T cells and NK cells to inhibit antibody production in nonmalignant B cells [13] [14] [15] . Anergic T cells turn off the CD40-mediated NF-κB-dependent activation of APCs, including B cells, through an unknown contact-dependent mechanism [36] [37] [38] . Together with previous reports 20, 21, 23, 36 , our findings suggest that engagement of CD30L on APCs by CD30 on T cells delivers bidirectional signals that negatively modulate the APC activation and the T cell effector functions. In this way, leukemia-induced CD30 + T cells would impair both humoral and cellular immunity in CLL 9 , including the cytotoxic response against malignant B cells. TNFL family members, including CD30L, CD40L and FasL, transmit intracellular signals upon binding to their cognate receptors 26, 39, 40 . Our experiments suggest that, in nonmalignant IgD + B cells, CD30L engagement inhibits CSR by hampering the CD40-mediated NF-κB-dependent transcriptional activation of downstream CH genes.
Consistent with previous findings 41, 42 , this inhibition would be dependent upon the CD30L ability to interfere with the recruitment of TRAFs to the CD40 receptor and turn off the subsequent IKK-dependent degradation of IκBα. Preliminary experiments suggest that, in nonmalignant IgD + B cells, CD30L-induced tyrosine and serine kinases interfere with CD40 signaling by inducing phosphorylation-dependent dissociation of TRAF2 43 from the CD40 cytoplasmic tail (A. Cerutti, E. C. Kim, A. Schaffer and P. Casali, unpublished data).
In CLL, CD30 + T cells would impair antibody production by inhibiting both the differentiation and survival of nonmalignant antibody-forming cell precursors. In CD40L-activated normal IgD + B cells, cross-linking of CD30L by CD30 hampers the activation of antiapoptotic NF-κB and up-regulates its cytoplasmic inhibitor IκBα. In the presence of FasL or exogenous TGF-β, these CD30L-activated IgD + B cells undergo increased apoptosis (A. Cerutti, E. C. Kim, A. Schaffer and P. Casali, unpublished data). Thus, abnormal CD30-CD30L interaction might deplete the pool of nonmalignant IgD + B cells by increasing their sensitivity to proapoptotic FasL and TGF-β expressed by leukemic CLL B cells [44] [45] [46] [47] . Upon CD30L engagement, leukemic B cells up-regulate the secretion of TNF-α, a cytokine that promotes the proliferation of neoplastic CLL B cells but not normal B cells 34, 35 . Consistent with this, CD30L-induced TNF-α enhances the TNFR2-dependent accumulation of malignant B cells and induces activation of NF-κB, a transcription factor that is critical for leukemic CLL B cell survival. 48 Thus, in CLL, abnormal CD30-CD30L interaction would selectively favor the TNF-α-dependent accumulation of the neoplastic clone. This, in turn, would further depress antibody production in nonmalignant IgD + B cells. In healthy subjects, professional APCs initiate both humoral and cellular immune responses by inducing CD40L on TH cells. By altering the microenvironment of secondary lymphoid organs, leukemic B cells would generate a molecular milieu that fosters CD30-dependent immune suppression rather than CD40-dependent immune help. Together with recent findings 49 ,our studies suggest that in vivo interruption of CD30-CD30L interaction could up-regulate the expression of CD40L, relieve immune suppression and decrease the accumulation of leukemic CLL B cells.
Methods
Cells. Normal PBMCs were obtained from ten healthy donors 8, 26, 50 . CLL PBMCs were isolated after informal consent from ten untreated CLL patients that satisfied the criteria for the disease 10 . Total T cells, total B cells, CD4 + T cells, CD8 + T cells and IgD + B cells were purified from PBMCs as described 8, 26, 50 . In selected experiments, IgD + B cells were extracted from tonsillar mononuclear cells. CLL B cells were purified to >98% using CD19-and CD5-conjugated magnetic beads (Miltenyi Biotec, Auburn, CA). TS1 and TS2 cells were magnetically sorted from purified total T cells with fluorescein isothiocyante (FITC)-conjugated monoclonal anti-CD8 (Southern Biotechnology Associates, Birmingham, AL), FITC-conjugated monoclonal anti-CD28 (Sigma, St. Louis, MO), anti-FITC magnetic beads and anti-FITC MultiSort Kit (Miltenyi Biotec). These T cells were used either for T-B cell cocultures or expanded with 50 U/ml of IL-2, 1:100 phytohemoagglutinin (Life Technologies Inc., Grand Island, NY) and irradiated feeder cells. CD3-conjugated magnetic beads (Miltenyi Biotec) were used to purify T cells from B-T cell cocultures. CL-01 B cells were as described 8, 26, 50 . Jurkat D1.1 T cells were from S. Lederman (Columbia University, New York), whereas MRC-5 fibroblasts were from American Type Culture Collection (Manassas, VA).
Cultures. Cells were cultured in RPMI 1640 medium supplemented with 10% heat inactivated fetal bovine serum (Life Technologies Inc.), 2 mM L-glutamine, 100 U/ml of penicillin and 100 µg/ml of streptomycin. B cells (1×10 6 /ml) and 1% paraformaldheyde-fixed TS1 cells or TS2 cells (1×10 6 /ml or 0.5×10 6 /ml) were cocultured in 96-microwell plates at a final volume of 200 µl. B cells were also cocultured with fixed CD4 + CD40L + TH cells (1×10 6 /ml). These TH cells were obtained by preincubating purified CD4 + T cells for 6 h with 50 ng/ml of phorbol myristate acetate (Sigma) and 500 ng/ml of ionomycin (Calbiochem-Novabiochem, San Diego, CA). T1, T2, T3 and T4 cells were sorted from cocultures in which 5×10 6 CD4 + T cells were incubated for 120 h with 1.25×10 6 , 2.5×10 6 , 5×10 6 or 20×10 6 CLL B cells, respectively, at a final volume of 5 ml. PCRs and Southern blots. Sγ-Sµ and Sα-Sµ switch circles were nested PCR amplified from 500 ng of genomic DNA extracted from purified B cells 26 . PCR products were hybridized with a radiolabeled probe that recognized the recombined Sµ region 26 . β-actin, IH-CH, Igβ, CD30 and CD40L cDNAs were PCR amplified as described 18, 33, 50 . Igβ was amplified by using a 5′-ATGGCCACGGCTGGCGTTGTCTC-3′ sense primer coupled 
